Project Details
Description
Activation of endogenous glucose production (EGP) was examined in non-diabetic (N=12) and type 1 diabetic (DM1, N=8) subjects while lowering plasma glucose (PG) from clamped euglycemia (~100 mg/dl; 5.6 mmol/L) to values just above the threshold for epinephrine (EPI) and glucagon secretion (~70 mg/dl; 3.9 mmol/L). To induce physiologic hyperinsulinemia (HIns), insulin infusions were fixed at 20% above the rate previously established that maintained euglycemia during somatostatin (250 5g/hr), glucagon (1.0 ng.kg-1.min-1), and GH (3.0 ng.kg-1.min-1) infusions without need for glucose infusion. In nondiabetic subjects, PG was reduced from 5.410.1 mmol/L to 3.910.1 mmol/L in the Experimental protocol, and held constant (5.310.2 mmol/L and 5.5mmol/L) in Control protocol. In the latter, with constant Hins (plasma insulin=12616 pmol/L) and euglycemia, EGP (estimated by [3H-3]-glucose) fell to values 40% of basal (p
Status | Finished |
---|---|
Effective start/end date | 1/1/01 → 5/31/08 |
ASJC
- Clinical Neurology
- Endocrinology, Diabetes and Metabolism
- Medicine(all)
- Biotechnology
- Demography
- Cardiology and Cardiovascular Medicine
- Nephrology
- Neurology
- Infectious Diseases
- Transplantation
- Genetics
- Speech and Hearing
- Radiology Nuclear Medicine and imaging
- Pulmonary and Respiratory Medicine
- Pharmacy
- Virology
- Surgery
- Immunology and Allergy
- Rheumatology
- Microbiology
- Immunology
- Hepatology
- Neuroscience(all)
- Nursing(all)
- Psychiatry and Mental health
- Pathophysiology
- Gastroenterology
- Spectroscopy
- Oncology
- Cancer Research
- Epidemiology
- Pediatrics, Perinatology, and Child Health
- Cell Biology
- Pathology and Forensic Medicine
- Pharmacology
- Pharmaceutical Science
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.